Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival

Objectives: Immune checkpoint inhibitors (ICIs) frequently induce immune related adverse events (irAEs) that may be associated with more favorable clinical outcomes. We aimed to evaluate the impact of all types of rheumatic adverse events (AEs) on overall survival (OS) and tumor response in patients treated with ICIs. Methods: We performed a single-center retrospective observational study to analyze the OS and tumor response in patients receiving ICIs who experienced a rheumatic AE compared to those who did not experience any AE. Results: From December 2010 to September 2018, 264 patients with any cancer type were included. Forty-three patients (16.3%) presented with at least one rheumatic AE. The median OS of patients with rheumatic AEs was significantly higher than that of patients without AEs, with 132 weeks (95% CI [69.3not reached]) and 42.7 weeks (95% CI [25.6-not reached]), respectively (P < 0.01). This result remained significant after multivariate analysis (HR 0.54, 95% CI [0.30-0.97], P < 0.05). Also, tumor response was better in patients with rheumatic AEs. Conclusion: The occurrence of rheumatic AEs in patients treated with ICIs is associated with better survival and tumor response. Therefore, it seems essential to detect rheumatic AEs as early as possible to allow rapid and optimal management, given the long-term response potential of these patients. (c) 2021 Socie & acute;te & acute; franc & cedil; aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.